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tumor response and survival after preoperative
chemoradiation for rectal cancer
Ik Yong Kim1, Sei Hwan You2 and Young Wan Kim1*Abstract
Background: Neutrophil-lymphocyte ratio (NLR) reflects the balance between pro- and anti-tumor immune activities.
We evaluated whether NLR is associated with pathologic tumor response and prognosis in rectal cancer patients that
underwent preoperative chemoradiaton therapy (CRT) with surgery.
Methods: One hundred two patients with rectal cancer that were treated by preoperative CRT followed by surgery were
enrolled. A total of 50.4 GY of radiation and 5-FU-based chemotherapy were delivered. An NLR ≥ 3 was considered to be
elevated. Pathologic tumor response based on ypTNM stage was categorized into two groups, good response (n = 35,
pathologic complete response and ypTNM I) and poor response groups (n = 67, ypTNM II, III, and IV).
Results: Twenty-five patients (24.5%) had elevated NLR. Multivariate analysis showed that an elevated CEA level
(p = 0.001), larger tumor (p = 0.03), and elevated NLR (p = 0.04) were significant predictors for a poor response. Poor
pathological tumor response and elevated NLR were risk factors for cancer-specific and recurrence-free survivals.
Conclusion: An elevated NLR before CRT can be used as predictors for poor tumor response and unfavorable prognostic
factors. Dominant pro-tumor activities of neutrophils or reduced anti-tumor immune response by lymphocytes, as
determined by NLR, may have a impact on poor tumor response and unfavorable prognosis.
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Preoperative chemoradiation (CRT) followed by total
mesorectal excision (TME) is advocated as a treatment for
locally advanced rectal cancer [1]. However, it is important
to identify patients based on their responsiveness to
preoperative CRT. Patients with pathologic complete
responses would have favorable oncologic outcomes, and
identification of patients with poor response could prevent
unnecessary radiation and surgery delay [2,3]. Diverse
clinical and molecular predictors for preoperative CRT
have been investigated, but there is currently no clear
consensus about reliable markers for pathologic tumor
response after preoperative CRT.
Inflammation is closely associated with tumorigenesis.
Colorectal cancers are infiltrated by various immune* Correspondence: youngwkim@yonsei.ac.kr
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unless otherwise stated.cells such as neutrophils, T and B lymphocytes, dendritic
cells, macrophages, natural killer cells, and mast cells
[4]. These cells produce cytokines, chemokines, and in-
flammatory mediators. Tumor-host interactions cause a
systemic inflammatory response, which leads to changes
in levels of circulating white blood cells (WBC) [5]. In
recent years, high neutrophil-lymphocyte ratio (NLR),
increased levels of neutrophils and decreased levels of
lymphocyte have been suggested to be poor prognostic
factors in colorectal cancer [6,7].
To date, there have been few studies examining the
role of NLR as a predictor for pathologic tumor
response and as a prognostic factor after preoperative
CRT in rectal cancer. It has been suggested that anti-
tumor immune response is part of the tumor cell death
process induced by ionizing radiation [8]. Accordingly,
tumor shrinkage may be caused by the host immune
response and can be a direct effect of radiation. Thus,
we postulated that host immune status as determined by. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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after preoperative CRT in rectal cancer. The aim of this
study was to evaluate the correlation of pretreatment
NLR with pathologic tumor response and prognosis in
rectal cancer patients who have undergone preoperative
CRT with TME.Methods
Patients
From October 1996 to November 2012, 111 patients
with rectal cancer who were treated with preoperative
CRT followed by TME were enrolled in this observa-
tional study. Patients with histologically confirmed rectal
adenocarcinoma within 15 cm from the anal verge were
included. Endorectal ultrasonography, computed tomog-
raphy scan and pelvic magnetic resonance imaging were
used for preoperative staging. All patients had stage T3
or T4 and/or node-positive disease and underwent a
TME-based major surgery after CRT. Nine patients were
excluded because they did not complete scheduled
chemotherapy or radiation therapy and did not undergo
radical resection. Finally, a total of 102 patients were
analyzed in this study. Informed consent was obtained
from all patients, and this study was approved by the
Institutional Review Board (No. YWNR-13-5-059).
Patient follow-up lasted until death or until the cut-off
date of February 28, 2013. Ten patients were lost to
follow-up. The median follow-up interval was 39 months
(range, 3–238 months).
The primary objective of this study was to evaluate the
correlation of pretreatment NLR with pathologic tumor
response and prognosis. Pathologic tumor response
based on ypTNM stage was categorized into two groups
as follows; good response group (n = 35, pathologic
complete response and ypTNM I) versus poor response
group (n = 67, ypTNM II III, and IV). Two patients were
diagnosed as stage IV after CRT and were included in
this study. The STROBE guidelines were used to ensure
the reporting of this study (Additional file 1) [9].Systemic inflammatory markers
Blood samples were obtained within 7 days before CRT.
WBC, neutrophil, lymphocyte, platelet counts, C-reactive
protein (CRP) and albumin levels were recorded. NLR was
calculated as the neutrophil count divided by the lympho-
cyte count using preoperative blood test results. Post-CRT
NLR data were obtained from laboratory results approxi-
mately four weeks after CRT. An NLR ≥3 was considered
elevated. The modified Glasgow prognostic score (mGPS)
was recorded as follows: score 0, CRP ≤10 mg/l; score 1,
CRP >10 mg/l and albumin ≥35 g/l; score 2, CRP >10 mg/l
and albumin <35 g/l [10].Preoperative chemoradiation
Preoperative CRT
All patients underwent three-dimensional conformal treat-
ment planning using computed tomography scan simula-
tion. The total radiation dose was 50.4 Gy. Radiation was
delivered to the whole pelvis (45 Gy in 25 fractions) with a
boost to the primary tumor (5.4 Gy in 3 fractions) over
5 weeks [11]. Intravenous chemotherapy (425 mg/m2 5-
fluorouracil and 20 mg/m2 leucovorin) was administered
during weeks 1 and 5 of radiation therapy.
Surgery, pathology, and adjuvant therapy
TME was performed by a single surgeon four to eight
weeks after CRT was completed [12]. A standardized
pathologic examination was performed, and the TNM
staging system, ypT and ypN were recorded according to
the American Joint Committee on Cancer (AJCC).
Three to eight weeks after the surgery, adjuvant chemo-
therapy (400–425 mg/m2 intravenous 5-fluorouracil and
20 mg/m2 leucovorin) was performed for five days, every
28 days for four cycles.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics
for Windows, Version 20.0 (IBM, Armonk, NY, USA). Both
student’s t-test for continuous variables and Chi-square
test (Fisher's exact test) for categorical variables were per-
formed. Logistic regression was used to identify the patho-
logic tumor response predictors. Survival analysis was
performed using the Kaplan-Meier method with the log
rank test and Cox proportional hazard model. A P-value
less than 0.05 was considered to be statistically significant.
Results
Twenty-five patients (24.5%) had elevated NLR (≥3). The
pathologic tumor response based on the ypTNM stage
was categorized into two groups as follows: good response
(pathologic complete response (n = 9) and ypTNM I (n =
26)) and poor response (ypTNM II (n = 34), III (n = 31),
and IV (n = 2)) groups.
Clinicopathologic characteristics
There were no differences in age, gender, tumor loca-
tion, operation type, or duration from CRT to definitive
surgery between the good and poor response groups. A
larger tumor diameter (≥3 cm) (p = 0.003), and elevated
carcinoembryonic antigen (CEA) level (≥5 ng/mL) (p =
0.003) were more common in the poor response group
(Table 1).
Hematological characteristics
The mean white blood cell (p = 0.04) and neutrophil
counts (p = 0.01) were higher in the poor response group.
There were no differences in the mean lymphocyte or
Table 1 Clinicopathologic characteristics (n = 102)
Pathologic
response*
Good Poor
Variable N (%) N (%) P
Age (years) <60 17 (48.6) 36 (53.7) 0.6
≥60 18 (51.4) 31 (46.3)
Gender Male 28 (80) 54 (80.6) 0.9
Female 7 (20) 13 (19.4)
Tumor location Upper (10.1-15 cm) 0 (0) 3 (4.5) 0.2
Mid (5.1-10 cm) 12 (34.3) 31 (46.3)
Low (<5 cm) 23 (65.7) 33 (49.3)
Operation type Low anterior
resection
30 (85.7) 56 (83.6) 0.8
APE or Hartmann
procedure
5 (14.3) 11 (16.4)
Duration (preoperative
CRT to surgery) (week)
<6 22 (62.9) 42 (62.7) 0.99
≥6 13 (37.1) 25 (37.3)
Tumor diameter (cm) <3 30 (85.7) 38 (56.7) 0.003
≥3 5 (14.3) 29 (43.3)
ypT classification 0 9 (25.7) 4 (6.0) <0.001
1 5 (14.3) 1 (1.5)
2 21 (60.0) 4 (6.0)
3 0 (0) 55 (82.1)
4 0 (0) 3 (4.5)
ypN classification 0 35 (100) 36 (53.7) <0.001
1 0 (0) 22 (32.8)
2 0 (0) 9 (13.4)
CEA (ng/mL) <5 29 (85.3) 35 (55.6) 0.003
≥5 5 (14.7) 28 (44.4)
*Good response group: pathologic complete response and ypTNM I, poor
response group: ypTNM II, III and IV.
APE, abdominoperineal excision; CRT, chemoradiation; CEA,
carcinoembryonic antigen.
Table 2 Hematological characteristics
Pathologic response*
Good Poor
Mean ± SD Mean ± SD P Reference range
White blood cell 7 ± 2 7.9 ± 2 0.04 (4.0–10.0) × 109 /L
Neutrophil 4.1 ± 1.5 4.9 ± 1.7 0.01 (1.8–7.5) × 109 /L
Lymphocyte 2.1 ± 0.7 2.1 ± 0.7 0.96 (1.0–2.8) × 109 /L
Pre-CRT NLR <3 33 (94.3%) 44 (65.7%) 0.001
≥3 2 (5.7%) 23 (34.3%)
Post-CRT NLR <3 20 (57.1%) 31 (47.7%) 0.4
≥3 15 (42.9%) 34 (52.3%)
Platelet 275 ± 42 315 ± 113 0.2 (165–360) × 109 /L
C-reactive protein 0.4 ± 0.3 1.4 ± 2.7 0.03 <0.03 mg/dL
Albumin 4.2 ± 0.4 4 ± 0.5 0.2 (3.3-6.1) g/dL
mGPS 0 33 (94.3%) 58 (86.6%) 0.2
1,2 2 (5.7%) 9 (13.4%)
*Good response group: complete pathologic response and ypTNM I, poor
response group: ypTNM II,III and IV.
SD, standard deviation; CRT, chemoradiation therapy; NLR, neutrophil-lymphocyte
ratio; mGPS, modified Glasgow prognostic score.
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identified more frequently in the poor response group (p =
0.001), and the mean level of CRP was higher in the poor
response group (p = 0.03). An elevated post-CRT NLR
(≥3) and mGPS of 1 or 2 was more common in the poor
response group; however, this difference was not statisti-
cally significant (p = 0.4 and p = 0.2, respectively) (Table 2).
Multivariate analysis of pathologic tumor response
predictors
After extensive univariate analysis, only significant vari-
ables (CEA, tumor diameter, NLR, neutrophil count, and
CRP) were included in the multivariable logistic regression
models. Logistic regression analysis showed that an ele-
vated CEA level (≥5 ng/mL) (p = 0.001), large tumor diam-
eter (≥3 cm) (p = 0.03), and elevated NLR (≥3) (p = 0.04)were significant predictors of poor pathologic response
(Table 3). Neutrophil count (p = 0.6) and CRP (p = 0.6)
were not significant.Survival analysis
There were 20 cases of cancer-specific deaths and 34 cases
of recurrences. In terms of cancer-specific survival, poor
pathologic tumor response based on ypTNM (II, III, and
IV) and elevated CEA level, and NLR were significant risk
factors in univariate analysis. The 5-year cancer-specific sur-
vival rates were 76.9% and 45.6% in patients with NLR < 3
and NLR ≥ 3, respectively (p = 0.01) (Figure 1). The 5-year
recurrence-free survival rate was 61.2% and 14.6% in
patients with NLR < 3 and NLR ≥ 3, respectively (p = 0.01)
(Figure 2).
Multivariate analysis using the Cox proportional haz-
ard model showed that poor tumor response (hazard ra-
tio (HR) = 10, p = 0.03) and elevated NLR (HR = 6.6, p =
0.02) were significant prognostic factors (Table 4). In
terms of recurrence-free survivals poor tumor response
(HR = 3.4, p = 0.001 and HR = 3.1, p = 0.002) and ele-
vated NLR (HR = 3.6, p = 0.01 and HR = 2.8, p = 0.03)
were adverse prognostic factors in both univariate and
multivariate analyses (Table 5).Discussion
The major finding of this study is that NLR prior to
preoperative CRT can predict pathologic tumor response
in patients with rectal cancer. In addtion, elevated NLR
was a risk factor for recurrences-free and cancer-specific
survivals.
Table 3 Predictors for poor pathologic tumor response
(ypTNM II, III, and IV): multivariate analysis
HR (95% CI) P
CEA (ng/mL) <5 1 0.001
≥5 13.2 (2.8 - 62.1)
Tumor diameter (cm) <3 1 0.03
≥3 3.6 (1.2 - 11.8)
NLR <3 1 0.04
≥3 5.2 (1.1 - 26.5)
C-reactive protein (mg/dL) 1.7 (0.3 - 11.8) 0.6
Neutrophil count (× 109 /L) 1.1 (0.8 - 1.6) 0.6
HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; NLR,
neutrophil-lymphocyte ratio.
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environment and can influence the environment through-
out the stages of tumor progression. Secreted cytokines and
chemokines mediate inflammatory cell recruitment, tumor
growth, angiogenesis and adaptive immune response sup-
pression [13]. In comparison, lymphocytic infiltration, pre-
dominantly CD4+ or CD8+ T cells, in the primary tumor is
recognized as an anti-tumor immune response, and a
prominent infiltration is associated with improved survival
in colorectal cancer [14,15]. Weak lymphocytic infiltration
of the tumor margin after liver resection is linked to poor
prognosis in patients with colorectal liver metastasis [16].
Thus, NLR, the ratio of neutrophils and lymphocytes,
reflects the balance between pro- and anti-tumor immuneFigure 1 Cancer-specific survival rates according to neutrophil-lymph
and 45.6% in patients with NLR < 3 and NLR≥ 3, respectively (p = 0.01).activities. Elevated NLR could reflect dominant pro-tumor
activities of neutrophils or reduced anti-tumor immune
response by lymphocytes. These may be the reason that
patients with elevated NLR showed unfavorable pathologic
tumor response and prognosis in this study.
A higher lymphocyte ratio in white blood cells has
been suggested as a pathologic complete response
predictor after CRT in locally advanced rectal cancer
[17,18]. However, in our study, the lymphocyte counts
and ratios were not significantly different when the good
and poor response groups were compared. Krauthamer
et al. [19] studied predictors of tumor response to pre-
operative CRT in rectal cancer and determined that
serum albumin (>3.5 mg/dl) and NLR (<5) were predic-
tors for complete pathologic response in clinical stage III
(n = 71) patients but not in clinical stage II patients.
They explained that no association between NLR and
clinical stage II disease may be due to small study sam-
ples. In our study, the albumin level was not a significant
factor. In addition, other clinical parameters such as
small tumor diameter and normal CEA level have been
shown to predict pathologic complete response after
preoperative CRT in rectal cancer [20,21], and these
were also significant predictors in our study.
In regard to recurrence and survival, an elevated NLR
is associated with poor outcome, and NLR has been
shown as a prognostic factor in patients with resectable
or unresectable colorectal cancer [22,23]. Specifically
in rectal cancer patients, NLR showed conflicting re-
sults with respect to survival. NLR was identified as anocyte ratio (NLR). The 5-year cancer-specific survival rates were 76.9%
Figure 2 Recurrence-free survival rates according to neutrophil-lymphocyte ratio (NLR). The 5-year recurrence-free survival rate was 61.2%
and 14.6% in patients with NLR < 3 and NLR≥ 3, respectively (p = 0.01).
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not in a study by Chiang et al. [25] However, neither
study focused on patients that underwent preoperative
CRT. Carruthers et al. [7] investigated 115 patients with
locally advanced rectal cancer that were undergoing
preoperative CRT and determined that NLR and the
presence of residual tumor (R) status were predictors
for recurrence and survival, but ypTNM stage was not
considered in their analysis. In a study by Krauthamer
et al. [19], NLR was evaluated not as a prognostic factor,
but as a predictor for tumor response. The pathologic
tumor stage (ypTNM) after CRT has been suggested as
a reliable prognostic factor for recurrence and survival
in locally advanced rectal cancer [26]. In our study,Table 4 Risk factors associated with cancer-specific survival
Age (years) < 60 vs. ≥ 60
Gender Male vs. female
Tumor location Upper, mid vs. low
Operation type LAR vs. APE or Hartma
Duration (preoperative CRT to surgery)(week) <6 vs. ≥6
Tumor diameter (cm) <3 vs. ≥3
ypTNM pCR,I vs. II,III,IV
CEA (ng/mL) < 5 vs. ≥ 5
NLR < 3 vs. ≥ 3
HR, hazard ratio; CI, confidence interval; NA, not applied; LAR, low anterior resection
complete response; CEA, carcinoembryonic antigen; NLR, neutrophil-lymphocyte ratpathologic tumor response based on ypTNM stage as
well as NLR was a significant risk factor for recurrence
and cancer-specific survivals.
In addition to NLR, other markers of systemic inflam-
matory response, such as CRP and mGPS (CRP and
albumin), have been shown to be risk factors for inferior
survival in colorectal cancer [6,10]. Toiyama et al. [27]
investigated correlations between levels of systemic in-
flammation markers such as CRP and NLR in 84 pa-
tients with locally advanced rectal cancer. They observed
that elevated CRP and ypTNM III stage were adverse
prognostic factors for overall survival and an elevated
CRP level was an independent risk factor for disease-free
survival. In our study, the mean level of CRP was higherUnivariate Multivariate
HR (95% CI) p HR (95% CI) P
1.1(0.4 − 2.7) 0.8 NA
1 (0.3 − 2.9) 0.9 NA
2.3 (0.9 − 5.6) 0.1 NA
nn 1 (0.3 − 3) 1 NA
0.5 (0.2 − 1.4) 0.6 NA
1.9 (0.8 − 4.5) 0.2 NA
11 (1.5 − 85) 0.02 10 (1.3 − 75) 0.03
3.3 (1.4 − 8.2) 0.01 1.8 (0.7 − 4.7) 0.2
10 (2–49) 0.01 6.6 (1.3 − 32) 0.02
; APE, abdominoperineal excision; CRT, Chemoradiation; pCR, pathologic
io.
Table 5 Risk factors associated with recurrence-free survival
Univariate Multivariate
HR (95% CI) p HR (95% CI) P
Age (years) < 60 vs. ≥ 60 1.2 (0.6 − 2.4) 0.5 NA
Gender Male vs. female 1.2 (0.5 − 2.6) 0.7 NA
Tumor location Upper, mid vs. low 1.4 (0.7 − 2.7) 0.4 NA
Operation type LAR vs. APE or Hartmann 0.6 (0.3 − 1.6) 0.4 NA
Duration (preoperative CRT to surgery) (week) <6 vs. ≥6 0.8 (0.4 − 1.6) 0.5 NA
Tumor diameter (cm) <3 vs. ≥3 1.5 (0.8 − 3.1) 0.2 NA
ypTNM pCR,I vs. II,III,IV 3.4 (1.7 − 6.8) 0.001 3.1 (1.5 − 6.2) 0.002
CEA (ng/mL) < 5 vs. ≥ 5 1.7 (0.8 − 3.7) 0.2 1.3 (0.6 − 2.9) 0.5
NLR < 3 vs. ≥ 3 3.6 (1.5 − 8.9) 0.01 2.8 (1.1 − 6.8) 0.03
HR, hazard ratio; CI, confidence interval; NA, not applied; LAR, low anterior resection; APE, abdominoperineal excision; CRT, Chemoradiation; pCR, pathologic
complete response; CEA, carcinoembryonic antigen; NLR, neutrophil-lymphocyte ratio.
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showed that the CRP level was not an independent risk
factor for poor pathological response. In addition, patients
with mGPS of 1 or 2 were more common in the poor re-
sponse group, but this did not reach statistical significance.
Recently, laboratory blood data such as thrombocytosis
and lymphocyte counts have been shown to have prognos-
tic value in rectal cancer [28,29]. Kawai et al. [29] demon-
strated that pre-CRT thrombocytosis is related to poor
pathological tumor regression and poor local recurrence-
free survival. In our study, the mean number of platelets
was higher in the poor response group, but the difference
was not statistically significant. Yasuda et al. [28] observed
that hematological parameters such as hemoglobin, albu-
min, lymphocyte percentage, platelet counts, CRP, and
fibrogen level were associated with tumor response. Low
lymphocyte count was an adverse risk factor for disease-
free survival in their study. We did not observe a difference
in lymphocyte counts between good and poor response
groups.
NLR can be obtained simply and readily in a routine
blood test; however, to date, there is no consensus about
an NLR cut-off value. A cut-off value of 3 or 5 for NLR
as a continuous variable has been studied in rectal
cancer [7,24,25]. In this study, we chose 3 as the cutoff
based on our own preliminary data analysis in which a
cutoff of 3 yielded the highest predictive ability in terms
of pathological tumor response and survival analysis.
Thus, it is important to identify the optimal cut-off value
to accurately predict pathologic tumor response and
patient prognosis after CRT.
The small sample size was a limitation of this study. A
growing body of evidence suggests that NLR is closely re-
lated to cardiovascular or cerebrovascular disease [30,31].
Another limitation of our study is that we did not evaluate
potential interactions between comorbid conditions and
rectal cancer. However, to the best of our knowledges, this
is the first study that has simultaneously explored theimpact of NLR on the pathologic tumor response and
prognosis in rectal cancer patients that were undergoing
preoperative CRT. Based on our results, elevated NLR
may be used as a predictor for advanced disease features.
Accordingly, patients with elevated pretreatment NLR
may be considered for more aggressive preoperative or
adjuvant treatment [32,33].Conclusion
In conclusion, an elevated NLR prior to preoperative
CRT can be used as a poor pathologic tumor response
predictor in patients with rectal cancer. An elevated
NLR can identify patients at high risk for recurrence and
cancer-specific death. Dominant pro-tumor activities of
neutrophils or reduced anti-tumor immune response by
lymphocytes, as determined by elevated NLR, may have
a impact on poor tumor response and unfavorable prog-
nosis in terms of recurrence and survival.Additional file
Additional file 1: The STROBE guidelines were used to ensure the
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